US 11,787,870 B2
Pharmaceutical composition for preventing or treating cancer comprising LRIT2 inhibitor as active ingredient
Kyoung Wan Yoon, Seongnam-si (KR); Youn Kyung Houh, Seongnam-si (KR); Bu-Nam Jeon, Seongnam-si (KR); Jinyoung Sohn, Seongnam-si (KR); Yun Yeon Kim, Seongnam-si (KR); Suro Lee, Seongnam-si (KR); Joo-Yeon Chung, Seongnam-si (KR); and Areum Jeong, Seongnam-si (KR)
Assigned to GENOME AND COMPANY, Seongnam-si (KR)
Appl. No. 17/41,220
Filed by GENOME AND COMPANY, Seongnam-si (KR)
PCT Filed May 15, 2019, PCT No. PCT/KR2019/005853
§ 371(c)(1), (2) Date Sep. 24, 2020,
PCT Pub. No. WO2019/221516, PCT Pub. Date Nov. 21, 2019.
Claims priority of application No. 10-2018-0055909 (KR), filed on May 16, 2018.
Prior Publication US 2021/0009710 A1, Jan. 14, 2021
Int. Cl. C07K 16/28 (2006.01); A61P 35/00 (2006.01); C12N 15/113 (2010.01)
CPC C07K 16/2896 (2013.01) [A61P 35/00 (2018.01); C12N 15/1138 (2013.01); C07K 2317/55 (2013.01)] 10 Claims
 
1. A method for treating cancer in a subject, comprising:
administering, to the subject, a pharmaceutical composition,
wherein the pharmaceutical composition comprises a substance that binds to LRIT2 protein as an active ingredient,
wherein the substance that binds to LRIT2 protein is a neutralizing antibody or a fragment thereof which specifically binds to the LRIT2 protein.